Masimo (NASDAQ:MASI) Raised to Buy at Stifel Nicolaus

Masimo (NASDAQ:MASI - Get Free Report) was upgraded by equities research analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating in a research note issued on Monday, Marketbeat Ratings reports. The brokerage presently has a $170.00 price objective on the medical equipment provider's stock, up from their prior price objective of $148.00. Stifel Nicolaus' price target would suggest a potential upside of 23.09% from the company's current price.

Other equities analysts have also issued reports about the company. Wells Fargo & Company upgraded Masimo from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $117.00 to $160.00 in a research report on Monday, March 25th. Jefferies Financial Group reiterated a "hold" rating and issued a $121.00 price objective (up from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. BTIG Research boosted their price objective on Masimo from $145.00 to $166.00 and gave the company a "buy" rating in a research report on Monday, March 25th. Needham & Company LLC lowered Masimo from a "buy" rating to a "hold" rating in a research report on Wednesday, January 3rd. Finally, Piper Sandler boosted their price objective on Masimo from $70.00 to $117.00 and gave the company a "neutral" rating in a research report on Monday, February 26th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $137.43.

Masimo Price Performance

Masimo stock traded up $0.19 during mid-day trading on Monday, hitting $138.11. 452,040 shares of the company were exchanged, compared to its average volume of 592,937. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. The business has a fifty day moving average of $135.48 and a 200 day moving average of $113.18. Masimo has a 1-year low of $75.22 and a 1-year high of $198.00. The company has a market capitalization of $7.31 billion, a PE ratio of 91.46 and a beta of 0.97.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.43. The firm had revenue of $548.90 million during the quarter, compared to analysts' expectations of $545.69 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The company's quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.32 EPS. As a group, sell-side analysts expect that Masimo will post 3.51 earnings per share for the current year.

Institutional Investors Weigh In On Masimo

Several institutional investors have recently bought and sold shares of MASI. Vanguard Group Inc. raised its stake in shares of Masimo by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider's stock worth $560,421,000 after purchasing an additional 26,473 shares in the last quarter. Capital Research Global Investors raised its stake in shares of Masimo by 6.4% during the 4th quarter. Capital Research Global Investors now owns 2,269,189 shares of the medical equipment provider's stock worth $265,972,000 after purchasing an additional 136,617 shares in the last quarter. State Street Corp raised its stake in shares of Masimo by 1.6% during the 1st quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider's stock worth $251,928,000 after purchasing an additional 27,261 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Masimo by 6.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,607,310 shares of the medical equipment provider's stock worth $188,393,000 after purchasing an additional 93,861 shares in the last quarter. Finally, Eminence Capital LP bought a new stake in shares of Masimo during the 3rd quarter worth approximately $90,859,000. Institutional investors own 85.96% of the company's stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.